Compare POZN to:
Real-Time: 6.99 -0.07 (-0.99%) 9:36am ET
| Last Trade: | 7.06 |
|---|---|
| Trade Time: | Nov 30 |
| Change: | 0.00 (0.00%) |
| Prev Close: | 7.06 |
| Open: | N/A |
| Bid: | 6.86 x 300 |
| Ask: | 7.12 x 100 |
| 1y Target Est: | 8.50 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 4.50 - 8.42 |
| Volume: | 0 |
| Avg Vol (3m): | 93,710.9 |
| Market Cap: | 210.56M |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.17 |
| Div & Yield: | N/A (N/A) |
| Fri, Nov 20 | POZEN Announces Start of Enrollment For PA32540 Phase 3 ProgramBusiness Wire |
| Fri, Nov 6 | POZEN INC /NC FinancialsEDGAR Online Financials |
| Mon, Nov 2 | POZEN INC /NC Files SEC form 10-Q, Quarterly ReportEDGAR Online |
| Fri, Oct 30 | POZEN To Present at the Credit Suisse Healthcare ConferenceBusiness Wire |
| Wed, Oct 28 | Pozen hits on profit, misses on revenueat bizjournals.com |
| Wed, Oct 28 | POZEN Inc. Earnings Call scheduled for 11:00 am ET todayCCBN |
| Wed, Oct 28 | POZEN INC /NC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online |
| Wed, Oct 28 | POZEN Reports Third Quarter 2009 ResultsBusiness Wire |
| Wed, Oct 28 | Q3 2009 POZEN Inc. Earnings Release - Before Market OpenCCBN |
| Tue, Oct 27 | Results of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk of Upper GI Damage in Healthy AdultsBusiness Wire |
Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for NASDAQ, NYSE and Amex.See also delay times for other exchanges.